Coronavirus Update: No Mortality Gains From Remdesivir In WHO Trial, Gilead Questions Results

Trial Involved 11,000 Patients

 
• By Scrip Team
  
WHO
The SOLIDARITY trial results have been praised by academic researcher leaders, but questioned by Gilead.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip